Clinical studies have demonstrated that it exhibits potent antitumor activity in patients with NTRK fusion positive cancer, such as those with TPM3–NTRK1 in lung cancer [140] and CTRC–NTRK1 in pancreatic ductal adenocarcinoma [141]. This evidence concerns the gene NTRK1 and lung carcinoma.